The analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.
This study found that immune checkpoint inhibitor therapy in patients with cancer could aggravate cardiovascular inflammation and subsequent cardiovascular or cerebrovascular events.
The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
The Theranica Biotherapeutics remote electrical neuromodulation device is now cleared for the acute treatment of migraine with or without aura in adults, without limitation to episodic migraine.
The lead investigator of the study and assistant professor of neurology at University of Colorado School of Medicine, Jacob Pellinen, MD, spoke to the importance of identifying nonmotor seizures.
In an interview with Targeted Oncology, Daniel A. Vorobiof, MD, discussed the evolution of the breast cancer treatment landscape and the emerging role of genomic testing in this space during Breast Cancer Awareness Month.
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
Genmab recently announced positive topline results from part 2 of the Phase 3 CASSIOPEIA study examining daratumumab monotherapy as maintenance therapy to treat patients diagnosed with multiple myeloma.